Patients with metastatic soft-tissue sarcoma can benefit from systemic therapy, but the best drug combinations for the different disease subtypes remain to be established. Recently, great emphasis has been placed on histology-based chemotherapy regimens. Herein, we discuss the results of a recently published study demonstrating that some of these regimens are not superior to standard-of-care chemotherapy in the neoadjuvant setting.

中文翻译：

---

肉瘤：组织型量身定制的新辅助疗法能否改善预后？

转移性软组织肉瘤患者可以从全身治疗中受益，但是针对不同疾病亚型的最佳药物组合仍有待建立。近来，已经高度重视基于组织学的化学疗法。本文中，我们讨论了最近发表的一项研究的结果，该研究表明，在新辅助治疗中，这些方案中的某些方案并不优于护理标准化疗。